Vor BiopharmaVOR
VOR
About: Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
Employees: 168
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
300% more call options, than puts
Call options by funds: $28K | Put options by funds: $7K
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
13% less funds holding
Funds holding: 52 [Q4 2024] → 45 (-7) [Q1 2025]
36% less capital invested
Capital invested by funds: $67.6M [Q4 2024] → $43.1M (-$24.5M) [Q1 2025]
40.62% less ownership
Funds ownership: 88.75% [Q4 2024] → 48.13% (-40.62%) [Q1 2025]
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
50% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 18
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$0.40
84%
downside
Avg. target
$2.60
4%
upside
High target
$6
140%
upside
4 analyst ratings
1 positive
25%
3 neutral
75%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth | 20%upside $3 | Buy Upgraded | 30 Jun 2025 |
Baird Jack Allen | 60%downside $1 | Neutral Maintained | 27 Jun 2025 |
Wedbush David Nierengarten | 84%downside $0.40 | Neutral Reiterated | 26 Jun 2025 |
JMP Securities Silvan Tuerkcan | 140%upside $6 | Market Perform Downgraded | 9 May 2025 |
Financial journalist opinion
Based on 6 articles about VOR published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer
CAMBRIDGE, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Sandy Mahatme as Chief Financial Officer and Chief Business Officer, effective July 9, 2025.
Neutral
GlobeNewsWire
1 week ago
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of June 26, 2025, the Board of Directors granted Jean-Paul Kress, the Company's Chief Executive Officer, an option to purchase 83,296,638 shares of Vor Bio's common stock in connection with the commencement of his employment. The foregoing stock option was granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
Positive
Benzinga
1 week ago
Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market
H.C. Wainwright upgraded Vor Biopharma Inc. VOR, highlighting the company's “rebirth” following the in-licensing of telitacicept.
Positive
Zacks Investment Research
1 week ago
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.
Neutral
GlobeNewsWire
2 weeks ago
Vor Bio Announces $175 Million Private Placement
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $175 million, before deducting expenses.
Neutral
GlobeNewsWire
2 weeks ago
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
-Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis -RemeGen receives initial payment of $125 million consisting of an upfront payment of $45 million plus $80 million of warrants, potential regulatory and commercial milestones exceeding $4 billion, as well as tiered royalties -Seasoned biopharma leader, Jean-Paul Kress, MD, appointed as Chief Executive Officer and Chairman of the Board, bringing proven track record in clinical development, commercialization, and strategic growth CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio, Inc. (Nasdaq: VOR) and RemeGen Co., Ltd.
Neutral
GlobeNewsWire
2 months ago
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.
Neutral
GlobeNewsWire
3 months ago
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025 $55.6 million private placement completed in December 2024 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update.
Neutral
GlobeNewsWire
4 months ago
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trials Despite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy (CGT) trials.
Neutral
GlobeNewsWire
5 months ago
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference.
Charts implemented using Lightweight Charts™